Get the Stockscreener App
11.05
6.45%
0.67
After Hours:
11.15
0.10
+0.90%
Helus Pharma Inc stock is traded at $11.05, with a volume of 1.52M.
It is up +6.45% in the last 24 hours and down -15.78% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$10.38
Open:
$10.3
24h Volume:
1.52M
Relative Volume:
0.96
Market Cap:
$807.42M
Revenue:
Net Income/Loss:
$-148.00M
P/E Ratio:
-2.4944
EPS:
-4.4299
Net Cash Flow:
$-135.66M
1W Performance:
+3.08%
1M Performance:
-15.78%
6M Performance:
+100.91%
1Y Performance:
+0.00%
1-Day Range:
$10.13
$11.15
1-Week Range:
$9.97
$12.73
52-Week Range:
$3.76
$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
11.05 | 807.42M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-26 | Initiated | Wells Fargo | Overweight |
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Helus Pharma Inc. (CN:HELP) Rallies 10.53% as Positive Momentum Sharpens Investor Focus - kalkine.ca
What Is Riding on Helus Pharma's Phase Three Readout? - Kalkine Media
Helus Pharma remains a buy ahead of key Phase 3 data for HLP003 expected in late 2026. - Pluang
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP) - Seeking Alpha
Helus Pharma (DB:R7E0)Rendimiento de beneficios e ingresos - Simply Wall Street
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) Options Chain - Yahoo! Finance Canada
Helus Pharma (NEOE:HELP)Análisis de acciones - Simply Wall Street
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance Singapore
Helus Pharma (HELP) will discuss depression and anxiety drugs at its investor webcast - Stock Titan
H.C. Wainwright reiterates Helus Pharma stock rating at buy - Investing.com
Helus Pharma to present updates on depression a... - Pluang
Helus Pharma to Host Investor Presentation on October 21, 2026 Highlighting HLP003 and HLP004 Development Programs - Quiver Quantitative
Helus Pharma to Host Investor Presentation on October 21, 2026Thu, 10/08/202607:30 - Helus Pharma
Helus Pharma Stock Under Pressure: Clinical Risk and Bearish Momentum Raise Correction Concerns - kalkine.ca
Helus Pharma Stock Drops 7.29% as Volatility Builds Ahead of Pivotal Phase 3 APPROACH Readout for HLP003 (CN:HELP) - kalkine.ca
Form 6-K Helus Pharma Inc. For: Oct 01 - StreetInsider
[6-K] CYBIN INC. Current Report (Foreign Issuer) - Stock Titan
Helus Pharma Stock Faces Renewed Pressure as Bearish Momentum Raises Correction Risk — Healthcare - kalkine.ca
Helus Pharma (NasdaqGM:HELP) Stock Forecast & Analyst Predictions - Simply Wall Street
HELPInterventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption - Simply Wall Street
Helus Pharma Inc.: Target Price Consensus and Analysts Recommendations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma Inc.: Financial Data Forecasts Estimates and Expectations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma (NasdaqGM:HELP)Rendimiento de beneficios e ingresos - Simply Wall Street
Helus Pharma Inc. (HELP) análisis del equipo directivo y de gestión - Simply Wall Street
No shareholder action is needed as Cybin (HELP) becomes Helus Pharma and keeps its ticker. - Stock Titan
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Canada
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Nigeria
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push - TipRanks
Helus Pharma (HELP) Officially Changes Legal Name from Cybin Inc. on October 1, 2026 - GuruFocus
Cybin rebrands to Helus Pharma, ticker symbol unchanged - Investing.com
CapEx per share of Helus Pharma Inc. – HAN:R7E - TradingView
Helus Pharma Announces Completion of Legal Name ChangeThu, 10/01/202607:30 - Helus Pharma
Helus Pharma Announces Completion of Legal Name Change - Yahoo Finance
Cybin Changes Legal Name to Helus Pharma - Yahoo Finance
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - Yahoo Finance
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - quiverquant.com
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - Yahoo Finance
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026Mon, 09/21/202607:30 - Helus Pharma
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma at Cantor conference: phase III readout in focus - investing.com
Helus Pharma at Cantor conference: phase III readout in focus - Investing.com India
Cybin Executive Chair Eric H. L. So Acquires 100,000 Shares in Voluntary Filing - Kalkine Media
CYBIN INC. (NASDAQ: HELP) Executive Eric So Holds Sole Authority Over 4.37 Million Shares - Kalkine Media
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - MarketBeat
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Helus Pharma Inc Stock (HELP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Halstead Michael | Chief Executive Officer |
Sep 21 '26 |
Buy |
13.47 |
100,000 |
1,347,050 |
168,568 |
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| So Eric H. L. | Executive Chair |
Sep 08 '26 |
Buy |
12.39 |
100,000 |
1,238,670 |
4,465,014 |
| Glavine Paul | Chief Growth Officer |
Sep 08 '26 |
Buy |
12.47 |
100,000 |
1,247,190 |
4,271,252 |
| So Eric H. L. | Executive Chair |
Sep 04 '26 |
Buy |
12.09 |
100,000 |
1,208,900 |
4,365,014 |
| Glavine Paul | Chief Growth Officer |
Sep 03 '26 |
Buy |
11.78 |
100,000 |
1,178,280 |
4,171,252 |
| So Eric H. L. | Executive Chair |
Sep 01 '26 |
Buy |
11.80 |
95,000 |
1,121,475 |
4,265,014 |
| Glavine Paul | Chief Growth Officer |
Aug 31 '26 |
Buy |
11.59 |
90,000 |
1,042,677 |
4,071,252 |
4.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):